AZS Media related thread, page-719

First 719 Last

Share
Profile

Follow
dolcevita

30,374 Posts.

1858

27/09/23

11:47

Post #: 70049933
Share

Originally posted by mrplough: ↑

I very much doubt SQM will come back with an offer anywhere close to where Tony, Mark and most shareholders would be happy selling out at.

Tony’s bare minimum aim is to get the MRE out, which should be early next year and 200MT+ all going well.

Mark Creasy is known to be a tough negotiator and has gone on record saying he’ll decide what to do once the scoping study (progressing well) has been completed.

if we follow their lead then you can realistically expect the SP to be a whole lot higher before they’d even start considering offers at the earliest, Q2-Q3 2024.

That’s my guess at least! It would be a huge gamble for someone to put in a bid for say $5bn at this stage, with no MRE or SS done, and I personally wouldn’t be happy to sell my shares for anything less than the $10 mark.

Expand

Originally posted by calmbeforestorm: ↑

I agree with your comments.

Why do all these people keep harping on about a takeover from SQM, MIN, etc etc thinking it will happen any day when it is crystal clear and in writing what Creasy intends to do plus looking at his history his MO is to sell only when he can maximise his return and that won't be before a feasibility study. A leopard does not change his spots! They need to get a good dose of reality and do research on Creasy.

They forget that it takes 2 to tango - to do a deal you need to seller who wants to sell. Who cares if MIN, SQM, etc etc want to buy Andover if the current owners have no interest in selling until a feasibility study is delivered.

Tony stated in an interview that Mark Creasy is a tough guy to do a deal with (he used more colourful language but not disrespectful to him). People think that just because he is 78 that he will sell cheaply - dream on as Billionaires keep piling on their wealth until they die.

BTW there are a lot of established lithium stocks that have fallen a lot in the last month or two (e.g. PLS by about 20%) but AZS SP has held up quite well.

Expand

Agree totally and should have read your comments before posting!

AZS Price at posting: $2.61 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 252 more messages in this thread...

First 719 Last

Add AZS (ASX) to my watchlist

AZS Media related thread, page-719

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News